KRAS protein

Cellular immunotherapy targets a common human cancer mutation

A team of researchers led by Steven Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, studied the use of immunotherapy for colorectal cancer. The team identified a method to target the cancer-causing protein produced by a mutant form of the KRAS gene. The patients who participated in the study experienced tumor regression after receiving this targeted immunotherapy approach. The New England Journal of Medicine published the study results on Dec. 8, 2016. Read more...

Cellular immunotherapy targets a common human cancer mutation

Edward Cowen discusses dermatology minerals on display at the NIH-Smithsonian exhibit

Posted: Dec 7, 2016

Edward Cowen, Senior Clinician in the Dermatology Branch, discussed the use of minerals in dermatology as part of the “Minerals in Medicine” exhibit in the NIH Clinical Research Center. The 18-month exhibit is put on by the Clinical Center and the Smithsonian National Museum of Natural History. Copper and sulfur are two of the minerals on display at the exhibit, and Cowen described how copper ions have been used for centuries as a disinfecting agent and sulfur is used in many different antibiotics and topical products. Read more...

Edward Cowen discusses dermatology minerals on display at the NIH-Smithsonian exhibit

Roberto Weigert produces Celldance video for ASCB 2016 Annual Meeting

Posted: Dec 7, 2016

Roberto Weigert, Senior Investigator in the Laboratory of Cellular and Molecular Biology, created one of the top-three videos for American Society for Cell Biology’s Celldance 2016. The theme for this year’s videos is “Tell your own cell story.” Weigert’s lab created, “Discovery Inside Living Cells in Multicellular Organisms.” He describes the video as every cell biologist’s dream of watching living cells work in living tissue as they keep the body alive. The video premiered during the ASCB 2016 Annual Meeting.

Roberto Weigert produces Celldance video for ASCB 2016 Annual Meeting

Rosenberg featured as Cancer Research Pioneer

Posted: Dec 2, 2016

CCR's Steven Rosenberg is featured in the December "Changing Lives" issue of Bethesda Magazine as a cancer research pioneer, part of the cutting edge medicine happening at NIH.  Rosenberg's "relentless" focus on cell therapy approaches has been shown to shrink tumors in some cancers.  "We are on the verge of some really important advances", says Rosenberg.  Read more...

Rosenberg featured as Cancer Research Pioneer

New study tests the safety and efficacy of combination therapy in adults with astrocytoma and glioblastoma

Posted: Dec 2, 2016

A two-part clinical trial of a multikinase inhibitor plus chemotherapy in patients with two types of brain tumors is enrolling in Bethesda, MD. The study will be open to patients with anaplastic astrocytoma, an uncommon malignant brain tumor that develops from star-shaped brain cells called astrocytes and glioblastoma, the most common and aggressive form of astrocytoma. Learn more...

New study tests the safety and efficacy of combination therapy in adults with astrocytoma and glioblastoma

Dr. Terri Armstrong appointed as senior investigator

Posted: Nov 29, 2016

Terri Armstrong, Ph.D. has joined the Neuro-Oncology Branch as a Senior Investigator.  Dr. Armstrong's work is focused on improving the assessment of patient outcomes measures and their incorporation into clinical trials.  She is also exploring the clinical phenotypes and genotypes associated with significant symptoms as well as the underlying biologic correlates of both symptoms and toxicity with the goal of developing interventions to improve patient outcomes.  Learn more…

Dr. Terri Armstrong appointed as senior investigator

Dr. Jagan Muppidi appointed as tenure track investigator

Posted: Nov 29, 2016

Jagan Muppidi, M.D., Ph.D., has joined the Lymphoid Malignancies Branch as a Stadtman Tenure Track Investigator. Dr. Muppidi will develop an independent research program centered on mechanisms of lymphomagenesis and collaborate on clinical investigations into the treatment of lymphoma.  Learn more...

Dr. Jagan Muppidi appointed as tenure track investigator

Dr. Pedro Jorge Batista appointed as tenure track investigator

Posted: Nov 28, 2016

Pedro Jorge Batista has been appointed as a Stadtman Tenure Track Investigator in the Laboratory of Cell Biology.  Dr. Batista's research focuses on the determination of the effect of RNA modifications on RNA biogenesis and function and the underlying mechanisms of why RNA molecules are modified, or how these modifications affect RNA maturation and function.

Dr. Pedro Jorge Batista appointed as tenure track investigator

Dr. Merlino elected as AAAS Fellow

Posted: Nov 28, 2016

The American Association for the Advancement of Science recently elected 391 members as Fellows of AAAS. Election as a Fellow honors members whose efforts on behalf of the advancement of science or its applications in service to society have distinguished them among their peers and colleagues.  We wish to congratulate Dr. Glenn Merlino, CCR Scientific Director for Basic Research and Co-Chief in the Laboratory of Cancer Biology and Genetics, on being elected as a member of the 2016 class of AAAS Fellows in the section on Biological Sciences!

Dr. Merlino elected as AAAS Fellow

Brigitte Widemann selected as Chief, Pediatric Oncology Branch

Posted: Nov 18, 2016

Dr. Brigitte Widemann has been selected as chief of CCR's Pediatric Oncology Branch. Widemann is a world-renowned leader in the development of early clinical trials for children and young adults with refractory cancers and genetic tumor predisposition syndromes. She and her colleagues have developed novel imaging methods for NF1-related plexiform neurofibromas and pioneered the development of early phase drug treatments for this patient population. CCR's Director, Tom Misteli, called Widemann "an incisive clinical researcher, compassionate physician and inspiring leader."  In October, she received the Humanitarian Award from the Children's Tumor Foundation.

Brigitte Widemann selected as Chief, Pediatric Oncology Branch

Andrea Apolo discusses why patients are never forgotten

Posted: Nov 18, 2016

Andrea Apolo, Investigator in the Genitourinary Malignancies Branch and Head of the Bladder Cancer Section, reflects on her clinical trial patients in the Bladder Cancer Advocacy Network's fall newsletter . She says: "Every time I use data derived from a patient in one of our clinical trials, I think about them; I think about their family, their loved ones. I remember the conversations we had while they were in clinic about politics, travel and the hobbies they enjoyed. I have memories of hundreds of study patients, and I am very grateful to each of them for their altruistic contribution to my research."

Andrea Apolo discusses why patients are never forgotten

Pages